OasisLMS

Available on-demand. Login or create an account to register to view the recording.

The use of kratom and kratom-derived products has expanded rapidly across the United States, with many individuals perceiving these substances as safe, natural alternatives for pain management, mood enhancement, and opioid withdrawal. More recently, highly concentrated and semi-synthetic products containing 7-hydroxymitragynine (7-OH), the primary opioid-active alkaloid of kratom, have emerged in commercial markets and online retailers. These products possess significant opioid receptor activity and are increasingly associated with tolerance, dependence, withdrawal, and other opioid-like adverse effects. Addiction medicine clinicians are now encountering patients using 7-OH products in detoxification, residential, outpatient, emergency, and primary care settings, often without adequate toxicology testing or standardized treatment guidance. This presentation will provide an evidence-based review of kratom and 7-OH pharmacology, emerging clinical trends, diagnostic challenges, and practical treatment strategies, including the use of medications for opioid use disorder when clinically indicated.

At the conclusion of this seminar, attendees should be able to:

1. Understand the pharmacology of 7-hydroxymitragynine (7-OH)
2. Recognize emerging products and misuse patterns
3. Identify clinical presentations of dependence and withdrawal
4. Implement evidence-based treatment approaches

How to claim your credits & download handouts for each webinar:

Under the "Course" tab (or "Content" tab):

1. Complete the required course materials.
2. Claim your credits by clicking the "Report Credit" or "Request Credit" button on the right above the course materials.

This webinar has been approved for a maximum 1, AOA Category 1-A CME credits. Physicians should claim only the credit commensurate with the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA) and AOAAM. The AOAAM is accredited by the AOA to provide continuing medical education for physicians.

Dr. Jason D. Kirby, DO, MBA, DFASAM   Dr. Jason D. Kirby, DO, MBA, DFASAM, is a nationally recognized leader in Addiction Medicine and currently serves as Chief Medical Officer of Recovery Centers of America. Recently named a Distinguished Fellow of ASAM, he brings a unique blend of clinical expertise, policy insight, and strategic leadership to advancing evidence-based addiction care. Dr. Kirby previously served as President of the Tennessee Society of Addiction Medicine and now holds a national leadership role as Treasurer on ASAM’s Executive Board, where he also chairs the Finance Committee. Board-certified in both Addiction Medicine and Family Medicine, his work spans clinical care, healthcare economics, and policy, with a focus on expanding access, improving quality, and shaping the future of addiction treatment. He also contributes to national guidelines and policy through multiple ASAM committees and currently serves as a Health Policy Fellow with AACOM, reflecting his ongoing commitment to driving meaningful change in healthcare systems and patient outcomes.